How Divamics' AI Platform is Revolutionizing Drug Discovery for Metabolic Diseases Divamics is making waves in drug discovery for metabolic diseases by leveraging AI and molecular dynamics for groundbreaking therapeutic advancements.

How Divamics' AI Platform is Revolutionizing Drug Discovery for Metabolic Diseases #China #Suzhou #AI_Platform #BGM1812 #Divamics

BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments BrightGene reveals positive Phase 2 trial results for its dual GLP-1R/GIPR agonist BGM0504 and a new amylin analogue, showcasing significant potential in diabetes management.

BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments #China #Suzhou #BrightGene #BGM0504 #BGM1812

BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment BrightGene Pharmaceutical unveiled encouraging Phase-2 results at the ADA Conference, highlighting its dual-GLP-1R/GIPR agonist's potential against Type-2 Diabetes and obesity.

BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment #China #Suzhou #BrightGene #BGM0504 #BGM1812

BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments BrightGene has announced positive Phase 2 results for BGM0504, a new dual GLP-1R/GIPR agonist, and preclinical data for BGM1812, showcasing their potential in weight management and diabetes treatment.

BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments #China #Suzhou #BrightGene #BGM0504 #BGM1812